AI precision testing for oncology.
Waiv (formerly Owkin Dx) is a Paris-based AI precision testing company spun out of biotech firm Owkin in 2026 with $33M in Series A funding. Built on 7+ years of clinical AI development, Waiv offers AI pathology models for oncology including cancer diagnostics, leveraging one of Europe's largest multi-institutional medical data networks.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountMar 2026
Create a free account to see which investors have funded this company.
Create Free Account
OneOncology empowers oncology practices with advanced tools and capabilities to help physicians d...
Healthcare company in Europe
Mehiläinen is a leading Finnish private healthcare company providing medical, health, and special...
Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...
Klick Health is a healthcare marketing and commercialization agency serving life sciences and pha...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
